ProMIS Neurosciences (PMN.TO) Stock Price
ProMIS Neurosciences Price
Revenue at ProMIS Neurosciences has contracted by 10.9% per year over the past 12 years to 10,000.00 CAD. ProMIS Neurosciences's net margin stands at -60,200.0%, down from -4,460.0% several years earlier. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
ProMIS Neurosciences stock price
ProMIS Neurosciences business model & stock analysis
Frequently asked questions about ProMIS Neurosciences
ProMIS Neurosciences Inc is a biotechnology company that focuses on the discovery and development of precision therapeutics for neurodegenerative diseases. Their business model revolves around utilizing their proprietary computational algorithms, which accurately predict disease-specific epitopes, to identify and develop novel antibody therapeutics. By specifically targeting and neutralizing toxic oligomers, ProMIS aims to prevent or slow down the progression of diseases like Alzheimer's and ALS. With a strong focus on precision medicine, ProMIS strives to provide tailored treatments that address the root causes of neurodegenerative disorders. Through their innovative approach, ProMIS Neurosciences Inc aims to improve the lives of patients suffering from these debilitating conditions.
ProMIS Neurosciences Inc primarily operates in the biotechnology and healthcare industries.
The main competitors of ProMIS Neurosciences Inc in the market are Biogen Inc, AC Immune SA, and Eli Lilly and Company.
ProMIS Neurosciences Inc, a leading biotechnology company, specializes in discovering and developing precision therapies for neurodegenerative diseases. Established in 2006, ProMIS focuses on targeting the toxic forms of proteins implicated in diseases like Alzheimer's, amyotrophic lateral sclerosis (ALS), and Parkinson's. By leveraging its unique algorithms and novel antibody discovery platform, the company aims to deliver highly specific and efficacious treatments while minimizing off-target effects. With a commitment to innovation and scientific excellence, ProMIS has amassed a vast portfolio of potential therapeutic candidates. As an industry leader, ProMIS Neurosciences Inc harnesses cutting-edge research to revolutionize neurodegenerative disease treatment.
ProMIS Neurosciences Inc has achieved several significant milestones. Firstly, the company has developed unique and innovative precision medicine programs targeting neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS. Furthermore, ProMIS has successfully identified and characterized specific epitope targets on toxic, misfolded proteins associated with these diseases. This allows for the development of highly selective antibody therapeutics to tackle these targets. ProMIS has also successfully generated multiple antibodies, including PMN310, targeting Alzheimer's, which showed a high selectivity for toxic protein aggregates in preclinical studies. These accomplishments highlight ProMIS Neurosciences Inc's dedication to advancing the treatment and understanding of neurodegenerative diseases.
ProMIS Neurosciences Inc primarily operates in Canada and the United States. The company is headquartered in Toronto, Ontario, Canada, and has a significant presence in various regions across North America. ProMIS Neurosciences is dedicated to developing precision medicine therapies for neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS. With a focus on using proprietary computational algorithms and expertise in disease-specific targets, ProMIS Neurosciences aims to address the unmet needs of patients globally. By leveraging its innovative approach, the company is actively advancing the development of novel antibody candidates for neurodegenerative disorders.
ProMIS Neurosciences Inc represents a commitment to advancing precision medicine for neurodegenerative diseases. The company's corporate philosophy centers around leveraging its proprietary technology and expertise to develop novel and specific antibody therapeutics. ProMIS Neurosciences Inc prioritizes the identification of unique targets on misfolded proteins associated with diseases like Alzheimer's, Parkinson's, and ALS. By focusing on these precise targets, the company aims to develop highly selective and effective treatments while minimizing the potential for off-target effects. Through its dedication to precision medicine, ProMIS Neurosciences Inc strives to make a significant impact on the lives of patients suffering from neurodegenerative disorders.
5 analysts currently rate the ProMIS Neurosciences stock: 4 recommend buying, 1 holding and 0 selling.
The ProMIS Neurosciences share (PMN.TO) is listed on 1 stock exchanges, including: Toronto (PMN.TO).
ProMIS Neurosciences Inc is a Canadian biotechnology company specializing in the discovery and development of precision medicines for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). The company utilizes a unique Precision Medicine platform to identify highly specific therapeutic antibody candidates that bind specifically to the disease-associated proteins of these conditions. Promis Neurosciences has four main business areas: Discovery, Development, Partnerships, and Integrated Solutions. In the Discovery phase, the company identifies specific disease-associated epitopes on the surfaces of proteins involved in neurodegenerative diseases. These epitopes form the basis for the development of molecular tools for the diagnosis, prognosis, monitoring, and treatment of these diseases. The Development phase focuses on advancing the antibody candidates identified by ProMIS Neurosciences in the Discovery phase. The company utilizes state-of-the-art methods in antibody production, optimization, and validation to improve the efficacy and safety of the candidates. Development also includes conducting preclinical studies and preparing for clinical trials to demonstrate the potential therapeutic applications of the antibody candidates. Through Partnerships, ProMIS Neurosciences collaborates with other companies and scientific institutions to validate, optimize, and license its technology platform and antibody candidates. These partnerships allow the company to share resources and knowledge to advance the development of its therapeutic approaches. ProMIS Neurosciences' integrated solution offering includes a range of tailored services for its customers. For example, the company provides specialized assays and test systems to evaluate the efficacy and selectivity of therapeutic antibodies. It also offers diagnostic tests and monitoring platforms for patients affected by neurodegenerative diseases. Additionally, ProMIS Neurosciences provides consultancy services for companies and scientific institutions interested in utilizing the company's Precision Medicine technology platform. ProMIS Neurosciences also offers a range of products for the diagnosis and monitoring of neurodegenerative diseases such as Alzheimer's and Parkinson's. These products include antibody-based assays specifically designed for disease-associated proteins, as well as diagnostic tests for clinical laboratories and for use in preclinical research. Overall, ProMIS Neurosciences provides a comprehensive and integrated solution for the discovery, development, and delivery of precision medicines for the treatment of neurodegenerative diseases. The company utilizes modern technologies and innovative approaches to develop highly specific and safe therapeutic antibodies for these serious conditions.
The revenue cannot currently be calculated for ProMIS Neurosciences.
The profit cannot currently be calculated for ProMIS Neurosciences.
The P/E ratio cannot be calculated for ProMIS Neurosciences at the moment.
The P/S cannot be calculated for ProMIS Neurosciences currently.
The Eulerpool Quality Score for ProMIS Neurosciences is 2/10.
The ISIN of ProMIS Neurosciences is CA74346M1095. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ProMIS Neurosciences is A14WN0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ProMIS Neurosciences is PMN.TO. The ticker symbol is used to trade ProMIS Neurosciences shares on the stock exchange.
ProMIS Neurosciences stock
ProMIS Neurosciences Peer Group
ProMIS Neurosciences Ticker
ProMIS Neurosciences FIGI
All fundamentals and in-depth analysis of ProMIS Neurosciences
Our stock analysis for ProMIS Neurosciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ProMIS Neurosciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.